Glutathione: What the Evidence Actually Shows for Skin Lightening

Well-characterised antioxidant and anti-melanogenic mechanism in vitro (tyrosinase inhibition via copper chelation; a shift from dark eumelanin toward lighter pheomelanin), but whether oral dosing delivers enough active glutathione to skin melanocytes is the open question.

The in-vitro redox and anti-melanogenic biology is well characterised, and human bioavailability studies show oral glutathione can raise body stores (with sublingual/precursor strategies an area of research).

Multiple small, short oral RCTs (mostly Asian women, 4-12 weeks) show modest, reversible melanin-index reductions on sun-exposed skin, but trials are small, narrow and sometimes industry-funded, with at least one clear null result; intravenous glutathione for whitening has essentially no efficacy evidence (the one placebo-controlled IV study missed significance).

Even where positive, the oral effect is modest, largely confined to sun-exposed skin and reverses on stopping; IV/injectable whitening has no convincing efficacy evidence.

Oral short-term tolerability is characterised (generally well tolerated up to ~6 months); long-term safety and the theoretical reduced-UV-photoprotection/skin-cancer question are unstudied, and IV/injectable use carries documented serious risks.

Heavily marketed for skin-lightening, but that use is unapproved and rests on small trials; injectable glutathione is approved only as a chemotherapy adjunct, not for whitening.

Moderate: reasonably confident the oral effect is modest and reversible and that IV whitening is unproven and risky.

The IV/injectable skin-lightening use is unapproved and the subject of an explicit regulatory warning (e.g. Philippine FDA Advisory 2019-182); injectable glutathione is approved only as a chemotherapy adjunct. Oral supplements are lower-concern.